Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches

Giuseppe Privitera, Daniela Pugliese, Loris Riccardo Lopetuso, Franco Scaldaferri, Matteo Neri, Luisa Guidi, Antonio Gasbarrini, Alessandro Armuzzi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the extent of their efficacy might be, at least partially, dependent on the timing of their introduction and on the subsequent management strategy. In this complex landscape, the potential role for a more dynamic approach with treatments based on sequencing and combining targeted therapies has been explored only minimally so far. In this review, we aim to explore the potential biological rationale behind the use of sequential and combination therapies in IBD, to summarise the current knowledge on this topic and to propose a management algorithm that combines these notions.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaTherapeutic Advances in Gastroenterology
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • INFLAMMATORY BOWEL DISEASE

Fingerprint

Entra nei temi di ricerca di 'Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches'. Insieme formano una fingerprint unica.

Cita questo